Press Releases

Date Title
Toggle Summary vTv Therapeutics Initiates Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease
Completed Phase 2 Trial Showed Positive Results Combating Alzheimer’s Disease High Point, North Carolina (May 19, 2015) vTv Therapeutics LLC (vTv) today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy),
View HTML
Toggle Summary TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program
High Point, North Carolina (March 5, 2015) TransTech Pharma, LLC today announced a global licensing agreement granting Calithera Biosciences, Inc. exclusive world-wide rights to research, develop and commercialize TransTech’s portfolio of hexokinase II inhibitors.
View HTML
Toggle Summary TransTech Pharma, LLC Announces Agreement with FDA on Special Protocol Assessment for TTP488 Phase 3 Trial in Patients with Mild Alzheimer's Disease
High Point, North Carolina (July 10, 2014) TransTech Pharma, LLC today announced that it has reached an agreement with the U.S. Food and Drug Administration Division of Neurology Products, under the Special Protocol Assessment (SPA) process, on the design of a single Phase 3 trial of TTP488 for the
View HTML
Toggle Summary Stephen L. Holcombe Appointed President of TransTech Pharma and High Point Pharmaceuticals
High Point, North Carolina (April 15, 2014) TransTech Pharma, LLC (“TransTech”) announced today that effective March 28, 2014, Stephen L. Holcombe, who previously served as the Company’s Senior Vice President and Chief Financial Officer, has been appointed to serve as the President of TransTech and
View HTML
Toggle Summary First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial
High Point, North Carolina (August 14, 2013) TransTech Pharma Inc. announced today important clinical trial data for its new diabetes drug. TTP399, a novel, liver-selective glucokinase activator (GKA), demonstrated clinical evidence of normalizing HbA 1c without inducing hypoglycemia in type 2
View HTML
Toggle Summary TransTech Pharma Completes End of Phase 2 Meeting with FDA for TTP488
High Point, North Carolina (July 1, 2013) TransTech Pharma Inc. announced today that it has successfully completed an End of Phase 2 meeting for TTP488 with the U.S. Food and Drug Administration (FDA). TTP488 is under development for the treatment of mild to moderate Alzheimer’s disease.
View HTML
Toggle Summary FDA Grants TransTech Pharma Inc. Fast Track Designation for TTP488 for the Treatment of Alzheimer's Disease
High Point, North Carolina (March 18, 2013) TransTech Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for TTP488, a new small-molecule chemical compound being developed for the treatment of Alzheimer’s disease.
View HTML
Toggle Summary TTP054, a Novel, Orally Active Drug for Glucose Control, Progresses Towards Completion of a Phase 2 Proof-of-Concept Clinical Trial in Type 2 Diabetics
High Point, North Carolina (November 1, 2012) TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013.
View HTML
Toggle Summary Novel, Oral Drug TTP488 Shows Promise for Disease Modification in Alzheimer’s Patients
High Point, North Carolina (October 29, 2012) A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer’s disease. TTP488 is a small-molecule drug that is the first to
View HTML